Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3YLVINYL)pyrimidine
The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-yl)pyrimidine, novel salt forms, and novel polymorphic forms of these salts.
1. An amorphous form of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate whose XRPD pattern substantially corresponds to that shown in FIG. 1 .
2. A polymorphic form of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate characterized by a powder x-ray diffraction pattern comprising at least one of the following peaks:
2Θ
11.02
20.01
22.06
24.66
32.13
33.35
34.61
35.96
38.65
40.23.
3. A polymorphic form of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate whose XRPD pattern substantially corresponds to that shown in FIG. 3 .
4. A polymorphic form of (R)-5-(E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate characterized by a powder x-ray diffraction pattern comprising at least one of the following peaks:
2Θ
9.43
12.24
16.24
18.38
19.18
19.48
21.52
22.89
23.08
24.28
30.77
31.27
32.36
33.09
34.86
37.26
37.63
39.47.
5. A polymorphic form of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate whose XRPD pattern substantially corresponds to that shown in FIG. 4 .
6. A polymorphic form of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate characterized by a powder x-ray diffraction pattern comprising at least one of the following peaks:
2Θ
5.05
10.81
14.06
15.20
17.43
23.47
24.21
25.52
26.95.
7. A polymorphic form of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate whose XRPD pattern substantially corresponds to that shown in FIG. 5 .